Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL14054045 | 0.98 | HRH3 (0.56) | HRH3HTR2ABCHEACHEGSK3B | |
| SCHEMBL14123652 | 0.91 | S1PR5 (0.51) | HRH3S1PR5 | |
| Bromide SCHEMBL14054947 | 0.90 | S1PR5 (0.50) | HRH3S1PR5 | |
| SCHEMBL14058819 | 0.83 | GSK3B (0.65) | HRH3GSK3B | |
| SCHEMBL14123713 | 0.82 | HRH3 (0.59) | HRH3MBTD1L3MBTL3L3MBTL1 | |
| Bromide SCHEMBL14054592 | 0.82 | GSK3B (0.63) | HRH3GSK3B | |
| SCHEMBL4267783 | 0.81 | GAA (0.66) | HRH3HTR2AMBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL14054465 | 0.81 | HRH3 (0.61) | HRH3HTR2AMBTD1L3MBTL3L3MBTL1 | |
| Bromide SCHEMBL14053619 | 0.81 | HRH3 (0.57) | HRH3MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL14123716 | 0.80 | HDAC6 (0.64) | HRH3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012162461-A1 | PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302569-A1 | PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302569-A1 | PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302569-A1 | PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP9, MMP1, MMP3 | HRH3 825/4885HTR2A 2552/4885BCHE 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.